Literature DB >> 29580849

Synthesis and biological evaluation of aminothiazoles against Histoplasma capsulatum and Cryptococcus neoformans.

Keisuke Ishita1, Stavros Stefanopoulos2, Ahmed Khalil1, Xiaolin Cheng1, Werner Tjarks1, Chad A Rappleye3.   

Abstract

The design and synthesis of a library of forty novel 2-aminoazole analogues as well as their evaluation as antifungal compounds against Histoplasma capsulatum and Cryptococcus neoformans is described. These structures were derived from N-[5-(1-naphthalenylmethyl)-2-thiazolyl]cyclohexanecarboxamide (41F5), a fungistatic agent previously identified through phenotypic screening (Antimicrob Agents Chemother. 2013;57:4349). Modifications to improve potency and water-solubility of 41F5 focused primarily on the 5-naphthalenyl group, the thiazole core, and the methylene linker between these two structural elements. In general, compounds with lipophilic [5+6] bicyclic ring systems, such as the 7-benzothiophenyl- and 4-indanyl groups, at the 5-position were 2-3 times more active against both fungal species as compared to 41F5. Also, introduction of a carbonyl group at the methylene linker of 41F5 resulted in a 2-3-fold increase in potency. These highly active compounds also showed generally low toxicities against murine P388D1 macrophages resulting in selectivity indices ranging from 63 to >200. Compounds that were highly active against fluconazole-sensitive C. neoformans strains had almost identical activity against fluconazole-resistant variants of this fungus indicating that 14α-demethylase is not their molecular target. Highly active compounds also retained activity against H. capsulatum phagocytosed into P388D1 macrophages.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aminothiazoles; Antifungal activity; Cryptococcus neoformans; Histoplasma capsulatum; Structure-activity-relationship

Mesh:

Substances:

Year:  2018        PMID: 29580849      PMCID: PMC5935597          DOI: 10.1016/j.bmc.2018.01.024

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  33 in total

1.  Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).

Authors:  Shawn A Messer; Ronald N Jones; Gary J Moet; Jeffrey T Kirby; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

Review 2.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

Review 3.  Activity-based protein profiling: from enzyme chemistry to proteomic chemistry.

Authors:  Benjamin F Cravatt; Aaron T Wright; John W Kozarich
Journal:  Annu Rev Biochem       Date:  2008       Impact factor: 23.643

Review 4.  Antifungal drug development: challenges, unmet clinical needs, and new approaches.

Authors:  Terry Roemer; Damian J Krysan
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

Review 5.  Current concepts in antifungal pharmacology.

Authors:  Russell E Lewis
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

6.  Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins.

Authors:  Marybeth A Maligie; Claude P Selitrennikoff
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 7.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

8.  Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist.

Authors:  Ruengwit Kitbunnadaj; Obbe P Zuiderveld; Bernard Christophe; Saskia Hulscher; Wiro M P B Menge; Edith Gelens; Erwin Snip; Remko A Bakker; Sylvain Celanire; Michel Gillard; Patrice Talaga; Henk Timmerman; Rob Leurs
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

9.  Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum.

Authors:  Jessica A Edwards; Megan M Kemski; Chad A Rappleye
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

Review 10.  Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

Authors:  Angela Loyse; Françoise Dromer; Jeremy Day; Olivier Lortholary; Thomas S Harrison
Journal:  J Antimicrob Chemother       Date:  2013-06-20       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.